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Seattle, WAA B S T R A C TBackground: The Veterans Health Administration (VHA) is the largest
integrated health care system in the United States and a major cancer
care provider. Objective: To use VHA database to conduct a
population-based study of patterns of myelosuppressive chemother-
apy use and to assess the incidence and management of febrile
neutropenia (FN) among VHA patients with lung, colorectal, or
prostate cancer or non-Hodgkin lymphoma (NHL). Methods: Data
were extracted for the initial myelosuppressive chemotherapy course
for 27,899 patients who began treatment in the period 2006 to 2011.
FN-related costs were deﬁned as claims containing FN diagnosis.
Results: Most patients were men (98.0%); most were 65 years or older
(55.8%). Patients received a mean 3.4 to 3.9 chemotherapy cycles/
course (median cycle duration 34–43 days). The incidence of FN
among patients with lung, colorectal, or prostate cancer or NHL was
10.2%, 4.6%, 5.4%, and 17.3%, respectively. Primary or secondary
prophylactic antibiotics/colony-stimulating factors were received by
21% and 12% of patients, respectively. Antibiotics were moreee front matter Copyright & 2014, International S
r Inc.
1016/j.jval.2014.06.009
.washington.edu.
ndence to: David C. Dale, MD, Department of Med
WA 98105.commonly given as primary or secondary prophylaxis for patients
with lung, colorectal, and prostate cancer; colony-stimulating factors
were more common for patients with NHL. Among patients with FN,
those with lung cancer had the highest inpatient mortality (10%);
patients with NHL had the highest costs ($24,571) and the longest
hospital length of stay (15.4 days). Conclusions: VHA cancer care was
generally consistent with National Comprehensive Cancer Network
recommendations; however, compared with the general population,
chemotherapy cycles were longer, combination chemotherapy was
used less, and treatment to prevent FN was used less, differences that
may be attributed to the unique VHA patient population. The impact
of these practices warrants further investigation.
Keywords: chemotherapy, febrile neutropenia, supportive care,
Veterans Health Administration.
Copyright & 2014, International Society for Pharmacoeconomics and
Outcomes Research (ISPOR). Published by Elsevier Inc.Introduction
The Veterans Health Administration (VHA) is the largest inte-
grated health care system in the United States and currently
provides care for more than 5 million patients at hospitals,
nursing homes, residential rehabilitation centers, and commun-
ity- and facility-based clinics [1–4].
Compared with the general US population, patients within the
VHA are more likely to be male, older, and have more comorbid-
ities [4]. Despite differences in age and the prevalence of comor-
bidities, the incidence of cancer within the VHA is similar to the
incidence of cancer among the US male population; the most
common types of cancers are lung and bronchus cancer, color-
ectal cancer (CRC), and prostate cancer [5,6].
Cancer is commonly treated with myelosuppressive chemo-
therapy, and neutropenia is a common, dose-limiting adverse
effect [7]. Neutropenia with fever (febrile neutropenia [FN]) can be
life-threatening and often requires immediate hospitalizationand treatment with intravenous antibiotics [8,9]. FN is associated
with increased inpatient mortality, lengthy hospital stays, and
signiﬁcant costs [8,10–12].
The VHA maintains a fully integrated claims database that
combines inpatient, outpatient, pharmacy, laboratory, and elec-
tronic medical records [2]. We used this database to conduct a
population-based study of patterns of myelosuppressive chemo-
therapy use and to assess the incidence and management of FN
among VHA patients with lung cancer, CRC, prostate cancer, or
non-Hodgkin lymphoma (NHL).Methods
Database
The VHA database includes records for more than 5 million
patients, organized into 22 Veterans Integrated Service Networks,ociety for Pharmacoeconomics and Outcomes Research (ISPOR).
icine, Box 356422, Health Sciences Building, AA 522, University of
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region.
Study Source Population
Patients who initiated one or more course of myelosuppressive
chemotherapy between January 1, 2006, and September 30, 2011,
were included. The index date was the date of chemotherapy
administration in the ﬁrst chemotherapy cycle. Patients were 18
years or older on the index date, continuously enrolled in the
VHA health plan for 90 days or more before the index date, and
diagnosed with lung cancer, CRC, prostate cancer, or NHL within
30 days of the index date. Cancer type was deﬁned by two or
more medical claims 7 or more days apart with the following
International Classiﬁcation of Diseases, Ninth Revision, Clinical Mod-
iﬁcation (ICD-9-CM) codes: lung cancer (162), CRC (153, 154),
prostate cancer (185), or NHL (200, 202). For patients who received
more than one course of chemotherapy during the study period,
only the ﬁrst course was evaluated. The follow-up period was the
time from the index date to either the end of follow-up or death.
Patients were excluded if they received myelosuppressive
chemotherapy or had a diagnosis of FN during the 90-day
preindex period, had two or more primary cancers (ICD-9-CM
codes 140.x-195.x, 199.x-209.x, 235.x-238.x), or had a medical
claim for a hematopoietic bone marrow or stem cell transplanta-
tion (ICD-9-CM code 41.0 or Healthcare Common Procedure Cod-
ing System codes S2150, 38240-38242) during the study period.
Outcomes
Chemotherapy treatment patterns
For each patient, each cycle was identiﬁed within the ﬁrst
chemotherapy course (deﬁned as starting on the index date and
ending on the ﬁrst day of the next cycle). Patients were excluded
if the between-cycle interval was less than 7 days. If the second
cycle had not commenced before day 60, both the cycle and the
course of chemotherapy were considered complete 60 days after
the index date. Subsequent cycles were similarly deﬁned, up to a
maximum of nine cycles. Outcomes were measured during the
follow-up period, inclusive of the index date.
Febrile neutropenia
Based on data from previously published studies [13,14], patient-
level FN incidence was approximated from inpatient or out-
patient claims with a diagnosis of neutropenia (ICD-9-CM 288.0).
Burden of FN included inpatient mortality (number of deaths
divided by the number of patients admitted), hospital length of
stay (LOS; based on relevant admission and discharge dates), and
mean health care costs (calculated per patient per cycle, with FN
adjusted to 2010 US dollars using the Consumer Price Index
component for medical care). FN-related costs were deﬁned as
claims containing FN as the primary or secondary diagnosis and
included FN-related outpatient, inpatient, prescription, and total
medical (outpatient þ inpatient þ pharmacy) costs.
Supportive care
Use of corticosteroids, antihistamines, and antiemetics per cycle
was deﬁned as one or more pharmacy claim. Administration of
colony-stimulating factors (CSFs) (ﬁlgrastim, pegﬁlgrastim, or
sargramostim) and/or antibiotics was characterized as prophy-
lactic or reactive use on the basis of the timing of use relative to
the administration of chemotherapy. CSF or intravenous anti-
biotic prophylaxis was deﬁned as ﬁrst administration within 5
days of chemotherapy initiation in any cycle. Oral-antibiotic
prophylaxis was deﬁned as the ﬁrst reported prescription ﬁll up
to 1 week before and up to 6 days after the receipt of chemo-
therapy. Primary prophylaxis, secondary prophylaxis, andreactive use were deﬁned as prophylaxis beginning with cycle
1, prophylaxis beginning with cycle 2 or subsequent cycles, and
no prophylaxis, respectively. Administration of intravenous anti-
biotics at the same time as an encounter for FN was classiﬁed as
reactive use, even if FN occurred within 5 days of chemotherapy
initiation [15–19].
Other variables measured included demographic character-
istics (age, sex, Charlson Comorbidity Index) and history of
anemia, other blood disorders, infection, or cancer as assessed
by relevant ICD-9-CM codes. The presence of comorbidities was
assessed during the 90-day preindex period.
Statistical Analyses
Descriptive analyses were used to summarize all study variables.
Means and standard deviations are provided for continuous
variables and numbers and percentages for categorical variables.Results
Patients’ Demographic and Clinical Characteristics
This study included 27,899 patients: 42.0% with lung cancer, 23.5%
with CRC, 19.1% with prostate cancer, and 15.5% with NHL. Their
demographic and clinical characteristics are presented in Table 1.
Chemotherapy Regimens
The ﬁve most common myelosuppressive chemotherapy agents
used to treat each tumor type were carboplatin/paclitaxel (36.3%),
carboplatin/etoposide (7.2%), cisplatin/etoposide (6.8%), carboplatin/
pemetrexed (4.4%), and pemetrexed (3.9%) for lung cancer; capeci-
tabine (37.5%), oxaliplatin (21.0%), ﬂuorouracil (9.3%), capecitabine/
oxaliplatin (6.3%), and mitomycin (4.9%) for CRC; docetaxel (41.7%),
mitomycin (13.0%), methotrexate (10.3%), bevacizumab (5.6%), and
hydroxyurea (3.7%) for prostate cancer; and rituximab (20.5%),
cyclophosphamide/doxorubicin/rituximab (13.7%), cyclophospha-
mide/doxorubicin/vincristine/rituximab (8.1%), cyclophosphamide/
rituximab (7.0%), and cyclophosphamide/vincristine/rituximab
(4.3%) for NHL. Patients received a mean  SD of 3.6  2.4, 3.9 
3.0, 3.4  2.9, and 3.9  2.5 cycles for lung cancer, CRC, prostate
cancer, and NHL, respectively, and the mean  SD cycle duration
was 39  15, 40  16, 44  15, and 39  14 days, respectively.
FN Incidence
The incidence of FN during the ﬁrst chemotherapy course was
10.2%, 4.6%, 5.4%, and 17.3% for lung cancer, CRC, prostate cancer,
and NHL, respectively (Table 2). For patients with NHL and lung
cancer, the incidence of FN was highest in cycle 1 and decreased
over subsequent cycles, whereas for those with prostate cancer
and CRC, the incidence of FN was relatively similar across
chemotherapy cycles (see Appendix Fig. 1 in Supplemental
Materials found at http://dx.doi.org/10.1016/j.jval.2014.06.009).
Except for patients with NHL, the management of FN was split
evenly between inpatient and outpatient settings; a higher
proportion of patients with NHL were treated in the inpatient
setting (Table 2).
Supportive Care
The use of corticosteroids, antihistamines, and antiemetics was
higher in certain tumor types. The use of corticosteroids and
antiemetics was highest in patients with lung cancer (many
received platinum-containing chemotherapy), and the use of
antihistamine was highest in patients with NHL (Table 2). Use
in subsequent cycles was similar to that in cycle 1 (data not
shown). Overall 21% of the patients received prophylactic
Table 1 – Patients’ demographic and clinical characteristics at baseline.
Characteristic Lung cancer
(N ¼ 11,715)
CRC
(N ¼ 6549)
Prostate cancer
(N ¼ 5322)
NHL
(N ¼ 4313)
Total population
(N ¼ 27,899)
Age (y), n (%)
18–25 0 (0.0) 3 (0.1) 0 (0.0) 4 (0.1) 7 (0.0)
26–34 3 (0.0) 20 (0.3) 0 (0.0) 22 (0.5) 45 (0.2)
35–54 920 (7.9) 684 (10.4) 112 (2.1) 467 (10.8) 2183 (7.8)
55–64 4788 (40.9) 2576 (39.3) 1189 (22.3) 1545 (35.8) 10098 (36.2)
Z65 6004 (51.3) 3266 (49.9) 4021 (75.6) 2275 (52.8) 15566 (55.8)
Sex, n (%)
Male 11429 (97.6) 6375 (97.3) 5322 (100.0) 4203 (97.5) 27327 (98.0)
Female 286 (2.4) 174 (2.7) 0 (0.0) 110 (2.6) 572 (2.1)
Charlson Comorbidity
Index,
mean  SD
5.3  3.5 5.1  3.4 4.6  3.1 3.7  2.6 4.9  3.3
History of other conditions, n (%)
Anemia 723 (6.2) 707 (10.8) 265 (5.0) 291 (6.8) 1986 (7.1)
Other blood disorders 401 (3.4) 244 (3.7) 106 (2.0) 219 (5.1) 970 (3.5)
Infection 682 (5.8) 581 (8.9) 149 (2.8) 262 (6.1) 1674 (6.0)
CRC, colorectal cancer; NHL, non-Hodgkin lymphoma.
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patients with lung cancer, CRC, or prostate cancer who received
primary prophylaxis were given primary prophylactic antibiotics
without concomitant CSF (Table 2). In contrast, more than halfTable 2 – FN and supportive care.
Findings Lung cancer
(N ¼ 11,715)
Overall FN Incidence,* n (%) 1195 (10.2)
Inpatient FN management† 752 (6.4)
Outpatient FN management† 638 (5.5)
Medications, cycle 1, n (%)
Corticosteroids 9271 (79.1)
Antihistamines 5204 (44.4)
Antiemetics 9909 (84.6)
Primary prophylaxis, n (%) 2656 (22.7)
Antibiotic only‡ 1410 (53.1)
CSF only‡ 915 (34.5)
Both CSF and antibiotic,‡,§ 331 (12.5)
Duration of prophylaxis (d), mean  SD 4.6  5.7
Secondary prophylaxis, n (%) 1676 (14.3)
Antibiotic only|| 664 (39.6)
CSF only|| 773 (46.1)
Both CSF and antibiotic§,|| 239 (14.3)
Duration of prophylaxis (d), mean  SD 5.1  5.0
Reactive use, n (%) 3847 (32.8)
Antibiotic only 2718 (70.7)
CSF only 478 (12.4)
Both CSF and antibiotic 651 (16.9)
Duration of reactive use (d), mean SD 5.6 (5.6)
CRC, colorectal cancer; CSF, colony-stimulating factor; FN, febrile neutro
* Patient-level incidence.
† If a patient had separate FN episodes that were managed in the inpatien
both inpatient and outpatient FN.
‡ Of those patients who received primary prophylaxis.
|| Of those patients who received secondary prophylaxis.
§ Either in combination or due to switching.the patients with NHL who received primary prophylaxis received
CSFs alone (Table 2). Among the 12% of patients who received
secondary prophylaxis, antibiotics alone were used more com-
monly in CRC and prostate cancer and CSF alone was used moreCRC
(N ¼ 6549)
Prostate cancer
(N ¼ 5322)
NHL
(N ¼ 4313)
302 (4.6) 287 (5.4) 744 (17.3)
147 (2.2) 184 (3.5) 571 (13.2)
188 (2.9) 168 (3.2) 377 (8.7)
2600 (39.7) 3154 (59.3) 3224 (74.8)
1076 (16.4) 1093 (20.5) 2187 (50.7)
4337 (66.2) 2419 (45.5) 2880 (66.8)
635 (9.6) 924 (17.4) 1599 (37.1)
546 (86.0) 709 (76.7) 417 (26.1)
67 (10.6) 173 (18.7) 797 (49.8)
22 (3.5) 42 (4.6) 385 (24.1)
6.2  8.4 4.5  5.4 5.0  6.5
619 (9.5) 452 (8.5) 641 (14.9)
332 (53.6) 241 (53.3) 147 (22.9)
248 (40.1) 157 (34.7) 370 (57.7)
39 (6.3) 54 (12.0) 124 (19.3)
5.7  4.7 5.1  4.8 4.9  5.2
1500 (22.9) 1289 (24.2) 1616 (37.5)
1212 (80.8) 1009 (78.3) 793 (49.1)
164 (10.9) 129 (10.0) 326 (20.2)
124 (8.3) 151 (11.7) 497 (30.8)
5.7 (6.1) 5.9 (5.9) 6.1 (6.4)
penia; NHL, non-Hodgkin lymphoma.
t setting and the outpatient setting, then that patient contributed to
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antibiotics and CSF varied considerably, and these were given
most commonly to patients with NHL.
Burden and Consequences of FN
Among patients hospitalized with FN, the mortality rate was
10.0%, 4.8%, 6.5%, and 5.6% for patients with lung cancer, CRC,
prostate cancer, and NHL, respectively. Mortality rates were
generally higher in the ﬁrst three chemotherapy cycles versus
subsequent cycles, ranging from 4.2% to 12.2% versus 0% to
15.8%, 4.6% to 5.1% versus 0% to 20.0%, 4.4% to 9.2% versus 0%
to 6.3%, and 3.2% to 7% versus 0% to 2.3%, respectively.
The mean  SD inpatient LOS across all cycles was 15.4  15.7,
12.4  13.9, 14.4  16.1, and 9.8  10.4 days for patients with lung
cancer, CRC, prostate cancer, and NHL, respectively, and the
average inpatient LOS ranged from 5.3 to 13.5, 3.8 to 17.5, 3.0 to
11.0, and 7.1 to 15.1 days, respectively.
The mean  SD FN-related total medical costs were $17,263 
$31,562, $17,335  $60,644, $13,242  $24,115, and $24,571 
$41,483 for patients with lung cancer, CRC, prostate cancer, and
NHL, respectively. Inpatient FN-related costs were higher than
outpatient costs for all cancer types: $26,507 ($36,647) versus
$1,091 ($1,336), $34,284 ($83,733) versus $1,039 ($1,110), $19,677
($27,990) versus $1,070 ($1,207), and $31,325 ($45,134) versus
$1,046 ($1,192), respectively.Discussion
This study represents the ﬁrst detailed description of cancer care
and FN within the VHA. The VHA is well suited for epidemio-
logical studies because it includes a large patient population,
provides a full continuum of care, uses an all-electronic health
record system, and captures extensive detail about patient care in
a fully integrated claims database. Furthermore, the VHA has
developed a nationwide standard to measure health care value
on the basis of cost, access, technical quality, patient’s functional
ability, and patient satisfaction.
Chemotherapy treatment appeared to be less aggressive
within the VHA than recommended by the National Comprehen-
sive Cancer Network guidelines [20–25]. For example, standard of
care is a combination chemotherapy regimen consisting of
Folinic acid (leucovorin), Fluorouracil (5-FU), and Oxaliplatin
(Eloxatin) for CRC and cyclophosphamide, hydroxydaunorubicin
(i.e., doxorubicin or Adriamycin), Oncovin (vincristine), and pre-
dnisone or prednisolone  rituximab for NHL; in the VHA,
standard-of-care regimens were not frequently observed.
Although guidelines recommend that chemotherapy regimens
evaluated in this study be administered once every 14 days or
once every 21 days, the interval between cycles in the VHA was
39 to 44 days. A number of factors may have contributed to longer
cycle durations, including patient preference, physician prefer-
ence (given the high number of comorbidities in this population),
dose delays due to adverse events, less aggressive treatment, a
focus on palliative care, inadequate symptom management
during the cycle, or a desire to avoid prophylactic CSFs.
Despite the observed differences in chemotherapy regimens
and cycle durations, the FN incidence in the VHA (4.6%–17.3%) is
similar to that observed in other studies (10%–16.8% [26,27]).
Patients with chemotherapy-induced FN are often hospitalized
[17]; however, some patients may be at low risk for complications
from FN and may be safely treated in the outpatient setting
[26,28–30]. In the VHA, approximately half the patients with FN
events were managed in the outpatient setting, the exception
being patients with NHL. The data suggest that there are either
patient subpopulations at low risk of developing FN or thatcancer is managed less aggressively within the VHA. In addition,
patients within the VHA may have farther to travel to access
hospital care and may prefer outpatient care when possible.
These patterns of care may delay or hinder access to inpatient
care for FN and may result in increased mortality or morbidity.
The burden and consequence of FN in the VHA is generally
consistent with other studies [8,10–12,26]. FN-related mortality
rates in the VHA versus previous studies were 10.0% versus 10.5%
to 21.2%, 4.8% versus 4.8% to 11.2%, and 5.6% versus 5.8% to 19.7%
for patients with lung cancer, CRC, and NHL, respectively, with
mean LOS of 12.4 days versus 7.1 to 9.5 days, 14.4 days versus 7.2
to 9.6 days, and 15.4 days versus 8.2 to 12.0 days, respectively.
Mortality due to FN in later chemotherapy cycles may be lower
than that in earlier cycles because few patients received chemo-
therapy beyond the fourth cycle. In addition, dose reductions,
which could not be effectively assessed in this study, would
reduce subsequent cycle FN and FN-related outcomes. The longer
LOS in the VHA may reﬂect more complex cases [8,10–12,26].
Total costs were similar at $17,263 versus $17,382 to $17,689,
$17,335 versus $19,667, and $24,571 versus $24,218 to $26,208 for
patients with lung cancer, CRC, and NHL, respectively [11,12].
Costs among studies should be compared with caution because
costs in the current study had wide SDs, likely due to a skewed
distribution and the impact of inﬂation. In addition, VHA costs
include slightly different categories than do other payers, such as
Medicare [31], and the metric for costs may be set differently than
in other health care systems.
The incidence and burden of FN can be affected by patterns of
supportive care. For example, nearly 80% of the patients with
lung cancer were receiving corticosteroids, potent antipyretics, in
cycle 1. Recent guidelines from the American Society of Clinical
Oncology and National Comprehensive Cancer Network recom-
mend prophylaxis with antibacterials and antifungals only for
patients expected to have severe and prolonged neutropenia and
that patients who develop FN should receive prompt antibacterial
therapy [15–17]. The American Society of Clinical Oncology and
the National Comprehensive Cancer Network recommend pri-
mary prophylaxis with CSFs only when the risk of FN is 20% or
more, and CSFs are not recommended for treating FN [15,16]. Our
study found that only 21% of VHA patients received primary
prophylaxis and an additional 12% received secondary prophy-
laxis. Among patients who received prophylaxis, most received
CSF only or antibiotic only; however, up to 24% and 19% received
both CSF and antibiotic as primary or secondary prophylaxis,
respectively, either in combination or because of switching. The
overall relative low use of prophylactic measures in the VHA may
be due to regimen modiﬁcations to decrease the intensity of
chemotherapy because of the presence of comorbidities and
advanced-stage disease. In our study, chemotherapy data were
insufﬁcient to calculate the actual dose intensity of the treat-
ments given to the patients or to analyze the frequency of
treatments having a speciﬁc risk of FN of more than 20%.
The current study has some limitations. First, most of the
patients within the VHA are elderly men; thus, the results of our
study may not be generalizable to the US cancer population.
Second, although use of CSFs and/or antibiotics was categorized
as prophylactic versus reactive based on timing relative to
chemotherapy administration, these agents was unknown. Third,
our study was limited to information captured in the electronic
medical record and errors of omission and commission may
occur. Fourth, overall mortality was not examined, and inpatient
mortality does not reﬂect overall mortality. Fifth, emergency
room encounters at a non-VHA facility are not captured in the
database, which identiﬁes only the location of encounters with
the VA station sufﬁx. Finally, there is no single ICD-9-CM code for
FN, and the true incidence of FN and FN-related burden can only
be approximated using algorithms. Although similar algorithms
V A L U E I N H E A L T H 1 7 ( 2 0 1 4 ) 7 3 9 – 7 4 3 743have been used to approximate FN in previously published
studies [13,14], some patients with severe neutropenia may have
been misclassiﬁed as having FN.
In summary, patterns of cancer care within the VHA were gene-
rally consistent with clinical recommendations. The most notable
differences included the aggressiveness of chemotherapy and
methods to prevent and treat FN. Many of these differences may
be due to the older, frailer patient population served by the VHA.Acknowledgments
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